By David Wild
The investigational oral formulation of tebipenem was comparable in efficacy and safety to IV ertapenem for the treatment of complicated urinary tract infections (cUTIs) or acute pyelonephritis (AP), according to phase 3 data presented at IDWeek 2020 (abstract LB-3).
“In the pivotal ADAPT-PO study, oral tebipenem was noninferior to ertapenem in the treatment of hospitalized patients with cUTI and AP,” said lead researcher Paul Eckburg, MD, a consultant to Spero